Meta-analysis of the relationship  between p21 Ser31Arg polymorphism and lung cancer susceptibility.
The  cyclin-dependent kinase inhibitor 1A (also known as p21) is thought to  be involved in tumor development by mediating cell cycle arrest through the  inhibition of cyclin/CDK activity. To explore the relationship of Ser31Arg  polymorphism in the p21 gene with the risk of developing lung cancer, we  performed an overall and stratified meta-analysis based on ethnicity, lung  cancer subtypes and source of controls, with six eligible studies (2366 cases  and 3320 controls). No significant variation in lung cancer risk was detected  in any of the genetic models in the overall, and the ethnicity-based and cancer  subtype-based subgroup analyses. However, in the subgroup analysis based on  source of controls, significant opposite associations were observed; a  significantly increased lung cancer risk was observed in the hospital-based  control subgroup, while a significantly decreased lung cancer risk was detected  in the mixed-source control and unknown-source control subgroups. In summary,  based on our meta-analysis, p21 Ser31Arg polymorphism does not appear to  act as an independent lung cancer risk factor and is more likely to act  together with other genetic and non-genetic factors in the development of lung  cancer; this needs further investigation.
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, PR China.
G
G
Lin
F
F
Fang
X-J
XJ
Yu
L
L
Yu
D019943:Amino Acid Substitution; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic; D012307:Risk Factors
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21